<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248793</url>
  </required_header>
  <id_info>
    <org_study_id>CR015916</org_study_id>
    <secondary_id>C0524T29</secondary_id>
    <nct_id>NCT01248793</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese
      patients with ankylosing spondylitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Golimumab is a type of tumor necrosis factor (TNF) inhibitor. TNF is a naturally occurring
      substance in the body, and this substance may cause long-term inflammation. Golimumab may
      help fight disease by blocking the activity of TNF in the body and reducing inflammation and
      pain. Each patient who is allowed to join the study will be put into a group randomly, like
      flipping a coin. Patients may get either golimumab or placebo (which looks like the drug
      being studied but has no active ingredients, for example a sugar pill). The chance that the
      patient will get golimumab is 1 to 1, so 50% chance to receive golimumab and 50% change to
      receive placebo. Patients who do not have an improvement in total back pain and morning
      stiffness at the Week 16 visit compared to when the patients entered the study, and are in
      Group 1 (placebo group), will receive golimumab 50 mg every 4 weeks starting at Week 16. If
      the patient is in Group 2 (golimumab 50 mg), they will continue to receive golimumab every 4
      weeks starting at Week 16. If the patient is in Group 1 and still receiving placebo
      injections, because there was improvement in total back pain at Week 16, they will receive
      golimumab 50 mg every 4 weeks starting from Week 24. If the patient is in Group 2 (golimumab
      50 mg) or are already receiving golimumab injections at week 24, they will continue to
      receive golimumab every 4 weeks. Safety will be monitored throughout the study, including
      drawing blood and looking at laboratory tests, vital signs (eg, blood pressure), and the
      frequency and type of adverse events (side effects). The patient will be in the study
      approximately 56 weeks. Patients will receive placebo or active compound (golimumab 50 mg
      subcutaneous injections) every four weeks until Week 48.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14</measure>
    <time_frame>Baseline and Week 14</time_frame>
    <description>BASFI is a participant's self-assessment, represented as a mean (Visual Analogue Scale [Score]; 0 cm [easy] to 10 cm [impossible]) of 10 questions, 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14</measure>
    <time_frame>Baseline and Week 14</time_frame>
    <description>BASMI is a combined score of 5 components of spine flexibility, ranging from 0 (least impairment) to 10 (most impairment). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Golimumab 50 mg SC injection every 4 weeks for 48 weeks</description>
    <arm_group_label>Golimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab (placebo group)</intervention_name>
    <description>Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Have a diagnosis of definite akylosing spondylitis for at least 3 months

          -  Have symptoms of active disease at screening and at baseline

          -  no active infections

        Exclusion Criteria:

          -  Have other inflammatory diseases that might confound the evaluations of benefit from
             the golimumab therapy

          -  Have complete ankylosis of the spine

          -  Have a history of latent or active granulomatous infection

          -  Have had a serious infection, or have been hospitalized for an infection, or have been
             treated with intravenous (IV) antibiotics for an infection within 2 months prior to
             first administration of study agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>May 25, 2012</results_first_submitted>
  <results_first_submitted_qc>May 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2012</results_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing Sponylitis, injection, golimumab, simponi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group I: Placebo</title>
          <description>Placebo SC injections every 4 weeks from Week 0 to Week 20(unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 48 if early escape; Golimumab 50 mg SC injections every 4 weeks from Week 24 to Week 48 if not early escape</description>
        </group>
        <group group_id="P2">
          <title>Group II: Golimumab 50 mg</title>
          <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 48</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I: Placebo</title>
          <description>Placebo SC injections every 4 weeks from Week 0 to Week 20(unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 48 if early escape; Golimumab 50 mg SC injections every 4 weeks from Week 24 to Week 48 if not early escape</description>
        </group>
        <group group_id="B2">
          <title>Group II: Golimumab 50 mg</title>
          <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 48</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="213"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="8.60"/>
                    <measurement group_id="B2" value="30.5" spread="10.27"/>
                    <measurement group_id="B3" value="30.5" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14</title>
        <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
        <time_frame>Week 14</time_frame>
        <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 20 if early escape</description>
          </group>
          <group group_id="O2">
            <title>Group II: Golimumab 50 mg</title>
            <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 20</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 14</title>
          <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
          <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24</title>
        <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
        <time_frame>Week 24</time_frame>
        <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 20 if early escape</description>
          </group>
          <group group_id="O2">
            <title>Group II: Golimumab 50 mg</title>
            <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 20</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Ankylosing Spondylitis Response (ASAS 20) at Week 24</title>
          <description>Number of patients who achieved a &gt;= 20% improvement in ankylosing spondylitis symptoms, including back pain, function, and inflammation</description>
          <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14</title>
        <description>BASFI is a participant’s self-assessment, represented as a mean (Visual Analogue Scale [Score]; 0 cm [easy] to 10 cm [impossible]) of 10 questions, 8 of which relate to the participant’s functional anatomy and 2 of which relate to a participant’s ability to cope with everyday life. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline and Week 14</time_frame>
        <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 20 if early escape</description>
          </group>
          <group group_id="O2">
            <title>Group II: Golimumab 50 mg</title>
            <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 20</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14</title>
          <description>BASFI is a participant’s self-assessment, represented as a mean (Visual Analogue Scale [Score]; 0 cm [easy] to 10 cm [impossible]) of 10 questions, 8 of which relate to the participant’s functional anatomy and 2 of which relate to a participant’s ability to cope with everyday life. A negative change from baseline indicates improvement.</description>
          <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="2.0967"/>
                    <measurement group_id="O2" value="-1.262" spread="2.5698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14</title>
        <description>BASMI is a combined score of 5 components of spine flexibility, ranging from 0 (least impairment) to 10 (most impairment). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline and Week 14</time_frame>
        <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (unless early escape at Week 16); Golimumab 50 mg SC injections every 4 weeks from Week 16 to Week 20 if early escape</description>
          </group>
          <group group_id="O2">
            <title>Group II: Golimumab 50 mg</title>
            <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 20</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 14</title>
          <description>BASMI is a combined score of 5 components of spine flexibility, ranging from 0 (least impairment) to 10 (most impairment). A negative change from baseline indicates improvement.</description>
          <population>Intent-to-treat population according to their assigned treatment group regardless of whether or not they receive the assigned treatment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.718"/>
                    <measurement group_id="O2" value="-0.42" spread="0.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo -&gt; Golimumab 50 mg</title>
          <description>Placebo SC injections every 4 weeks from Week 0 to Week 12 and early escape to receive Golimumab 50 mg SC injection every 4 weeks from Week 16 to Week 20; or Placebo SC injections every 4 weeks from Week 0 to Week 20 and crossed over to receive Golimumab 50 mg SC injections every 4 weeks from Week 24 to Week 48</description>
        </group>
        <group group_id="E2">
          <title>Golimumab 50 mg</title>
          <description>Golimumab 50 mg SC injections every 4 weeks from Week 0 to Week 48</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculous Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian Epithelial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Research</name_or_title>
      <organization>Janssen Research &amp; Development</organization>
      <phone>610-500-3369</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

